1 / 12

A Case study of Biotechnology: - How to use Biotechnology for Economic Development

Information Meeting on Intellectual Property Financing Organised by the World Intellectual Property Organisation (WIPO). A Case study of Biotechnology: - How to use Biotechnology for Economic Development . Theme 3: IP Financing in the Field of Patents By Iain C Shirlaw.

niveditha
Télécharger la présentation

A Case study of Biotechnology: - How to use Biotechnology for Economic Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Information Meeting on Intellectual Property Financing Organised by the World Intellectual Property Organisation (WIPO) A Case study of Biotechnology: - How to use Biotechnology for Economic Development Theme 3: IP Financing in the Field of Patents By Iain C Shirlaw Geneva, Switzerland, March 10, 2009 Active Investment Partners

  2. Introduction to Scotland • Population 5.1m • North West edge of Europe • Respect for Education • 14 Universities • Produces 1% of world’s published research • Graduation rate of 39.2%, from first degrees * (#1 in OECD) • 620 Life Science companies • 31,000 Life Science jobs • In 2007, 20 new Life Science companies formed • £3 billion contribution to the economy

  3. Scotland’s Biotechnology Fame Dolly the Sheep, and her lambs at Roslin

  4. Time line • 1413 St. Andrew’s University • 1495 Aberdeen Medical school • 1776 Adam Smith, “Wealth of Nations” • 1975 Scottish Development Agency • 1979 Venture Capital - Biogen • 1981 Spin outs Monotech and Bioscot • 1998 Pharmaceutical Proteins IPO • 2004 Cyclacel first European Biotech $100m funding • 2007 Haptogen acquired by Wyeth

  5. Fashions in IP development • Universities as source of learning and publishing. • 1980 MRI scanner first demonstrated Aberdeen, but GE / Fonar fought patent for use of MRI in cancer detection • Tech transfer and academic consultancies • Prof Stenlake’s Atracurium, £29m • Science Parks • 1971 Heriot Watt Research Park – first science park in Europe • Spin outs • Aurora • Drug Development Scotland • Cyclacel • Specialist IP asset developers and funders assets • British Technology Group • IP 2 IP • Braveheart • Exomedica

  6. 1980’s Life Science investing Corporate Legacy: Glaxo, Roche, Organon • Coats Paton, Monotech • Public Sector • Scottish Development Agency: • Inveresk, Cruachem, Bioscot • Venture Capital: • 3is, Apax, Transatlantic • Angel investors: • Biocure, Bill Bruce

  7. Financing Sources • Scottish Enterprise • LSBAS, Spin outs • IPOs • PPL, Scotia, Scotgen, Biocure, Shield • VC Funds • Scottish Equity Partners • Albany Ventures • Angel Syndicates • Archangel • Braveheart

  8. Government Investment Strategies

  9. 21st Century Development Frameworks • Public Sector Initiatives • SMART • Enterprise fellowship • Proof of Concept • Start-up • Co-Investment Fund • Venture fund • Gateway Advisory Services • Life Science Business Advisory group • Life Science Alliance • Bio Industry Association Scotland • Nexxus Bioscience Network • Angel Syndicates - Over 30 • Archangel • Braveheart • Highland • Tricap • Alybyn • Discovery • Clusters • Edinburgh Science Triangle • Pentlands Science Park • Edinburgh Technopole • Roslin Bio Centre • Bio Campus • Heriot Watt Research Park • West of Scotland Science Park • Nova Technology Park • City Science Glasgow • Lanarkshire Medi-park, Strathclyde Business Park • Scottish Enterprise Technology Park, East Kilbride • Dundee MediPark • Dundee Technology Park • Scottish Crop Research Science Park • Dundee Technopole • Aberdeen Science & Technology Park • Foresterhill • Edinburgh Bio Quarter - $1 billion to create one of world’s finest Biomedical centres

  10. The Next Issue - The funding gap

  11. Conclusion Progress IP from Upstream to Downstream to capture most economic value Scientific IP Invention Development Market Produce Create Business Attract Investment Grow Business Internationalise Corporatise One of a nation’s key assets is the ability of its people to invent, develop and commercialise. Scientists who are awarded government grants also have a responsibility to recognise the Value of IP to the economy and health and welfare of its people Biotechnology can be a very significant contributor to both local economic well being, and worldwide health improvements.

  12. Iain Shirlaw • Contact details: Active Investment Partners Management Services Consulting Investment • Iain.shirlaw@activeinvestmentpartners.com With Special Thanks and Acknowledgement in the preparation of this presentation to Alan Muir, Bill Harris, Pat Mc Hugh and Michael Cannon

More Related